On 15 December 2008, the US Food and Drug Administration (FDA) approved AMD3100 use in combination with granulocyte‐colony stimulating factor (G‐CSF) to mobilise bone marrow haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with Non‐Hodgkin's lymphoma (NHL) or multiple myeloma (MM) [46]. The gene discussed is CSF3; the disease is plasma cell myeloma.